Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/86642
Title:
Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.
Authors:
Ranson, Malcolm R; Davidson, Neville; Nicolson, Marianne; Falk, Stephen J; Carmichael, Jim; Lopez, Pedro; Anderson, Heather; Gustafson, Nancy; Jeynes, Allison; Gallant, Giles; Washington, Terri; Thatcher, Nick
Abstract:
BACKGROUND: In phase II trials, paclitaxel has been shown to have antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC). However, the survival and quality-of-life (QOL) benefits of paclitaxel used as a single agent compared with supportive care alone have not been assessed in a randomized clinical trial. METHODS: A total of 157 patients with stage IIIB or IV NSCLC who had received no prior chemotherapy were randomly assigned to receive either best supportive care alone (78 patients) or paclitaxel plus supportive care (79 patients). Paclitaxel was administered as a 3-hour intravenous infusion every 3 weeks. Supportive care included palliative radiotherapy and supportive therapy with corticosteroids, antibiotics, analgesics, antiemetics, transfusions, and other symptomatic therapy as required. The primary end point of the study was survival. Time to disease progression, response rate, adverse events, and QOL were secondary end points. RESULTS: Pretreatment characteristics were evenly distributed between the two arms. Survival was statistically significantly better in the paclitaxel plus supportive care arm than in the supportive care alone arm (two-sided P =.037) (median survival = 6.8 months versus 4.8 months). Cox multivariate analysis showed paclitaxel plus supportive care to be statistically significantly associated with improved survival (two-sided P =.048). QOL was similar for both treatment arms, except for the functional activity score of the Rotterdam Symptom Checklist, where QOL data statistically significantly favored the paclitaxel plus supportive care arm (two-sided P =.043). CONCLUSION: The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL.
Affiliation:
Christie Hospital and Wythenshawe Hospital, Manchester, U.K. malcolm.ranson@man.ac.uk
Citation:
Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. 2000, 92 (13):1074-80 J. Natl. Cancer Inst.
Journal:
Journal of the National Cancer Institute
Issue Date:
5-Jul-2000
URI:
http://hdl.handle.net/10541/86642
DOI:
10.1093/jnci/92.13.1074
PubMed ID:
10880550
Type:
Article
Language:
en
ISSN:
0027-8874
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRanson, Malcolm Ren
dc.contributor.authorDavidson, Nevilleen
dc.contributor.authorNicolson, Marianneen
dc.contributor.authorFalk, Stephen Jen
dc.contributor.authorCarmichael, Jimen
dc.contributor.authorLopez, Pedroen
dc.contributor.authorAnderson, Heatheren
dc.contributor.authorGustafson, Nancyen
dc.contributor.authorJeynes, Allisonen
dc.contributor.authorGallant, Gilesen
dc.contributor.authorWashington, Terrien
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2009-11-23T10:07:07Z-
dc.date.available2009-11-23T10:07:07Z-
dc.date.issued2000-07-05-
dc.identifier.citationRandomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. 2000, 92 (13):1074-80 J. Natl. Cancer Inst.en
dc.identifier.issn0027-8874-
dc.identifier.pmid10880550-
dc.identifier.doi10.1093/jnci/92.13.1074-
dc.identifier.urihttp://hdl.handle.net/10541/86642-
dc.description.abstractBACKGROUND: In phase II trials, paclitaxel has been shown to have antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC). However, the survival and quality-of-life (QOL) benefits of paclitaxel used as a single agent compared with supportive care alone have not been assessed in a randomized clinical trial. METHODS: A total of 157 patients with stage IIIB or IV NSCLC who had received no prior chemotherapy were randomly assigned to receive either best supportive care alone (78 patients) or paclitaxel plus supportive care (79 patients). Paclitaxel was administered as a 3-hour intravenous infusion every 3 weeks. Supportive care included palliative radiotherapy and supportive therapy with corticosteroids, antibiotics, analgesics, antiemetics, transfusions, and other symptomatic therapy as required. The primary end point of the study was survival. Time to disease progression, response rate, adverse events, and QOL were secondary end points. RESULTS: Pretreatment characteristics were evenly distributed between the two arms. Survival was statistically significantly better in the paclitaxel plus supportive care arm than in the supportive care alone arm (two-sided P =.037) (median survival = 6.8 months versus 4.8 months). Cox multivariate analysis showed paclitaxel plus supportive care to be statistically significantly associated with improved survival (two-sided P =.048). QOL was similar for both treatment arms, except for the functional activity score of the Rotterdam Symptom Checklist, where QOL data statistically significantly favored the paclitaxel plus supportive care arm (two-sided P =.043). CONCLUSION: The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectCancer Stagingen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Agents, Phytogenic-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshDisease Progression-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshPaclitaxel-
dc.subject.meshProportional Hazards Models-
dc.subject.meshQuality of Life-
dc.subject.meshSurvival Analysis-
dc.subject.meshTreatment Outcome-
dc.titleRandomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital and Wythenshawe Hospital, Manchester, U.K. malcolm.ranson@man.ac.uken
dc.identifier.journalJournal of the National Cancer Instituteen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.